Eric L. Nuermberger, M.D.

Eric L. Nuermberger, M.D.
Associate Professor of Medicine, Division of Infectious Diseases, Department of Medicine

Eric Nuermberger, M.D.
Read Complete CV.
Email Dr. Nuermberger

My primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials. A major goal is to identify new agents that can be combined with existing drugs to shorten the duration of TB therapy or allow more intermittent drug administration.

I am also working with an innovative flow-controlled in vitro pharmacodynamic system to gain a better understanding of the pharmacodynamics of drug efficacy and selection of drug-resistant mutants during exposure to currently used agents.

My secondary interest is the experimental chemotherapy of pneumonia caused by Streptococcus pneumoniae, the leading cause of community-acquired pneumonia in humans. The work uses a novel low-dose aerosol infection model that produces an isolated pneumonia in mice. This model may be particularly useful for evaluating the efficacy of antimicrobials that concentrate in the lung parenchyma relative to serum.

Publications

To read some of these publications online, click here . Please note that to read the full text of some of these articles requires that you have an online subscription to the journal.

1.   Williams, K. N., C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-9.
2.   Nuermberger, E., and D. A. Mitchison. 2009. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med 179:2-3.
3.   Converse, P. J., P. C. Karakousis, L. G. Klinkenberg, A. K. Kesavan, L. H. Ly, S. S. Allen, J. H. Grosset, S. K. Jain, G. Lamichhane, Y. C. Manabe, D. N. McMurray, E. L. Nuermberger, and W. R. Bishai. 2009. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun 77:1230-7.
4.   Tasneen, R., S. Tyagi, K. Williams, J. Grosset, and E. Nuermberger. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 52:3664-8.
5.   Subramanian, A. K., and E. L. Nuermberger. 2008. Tuberculosis in transplant recipients: diagnostic and therapeutic dilemmas. Transpl Infect Dis 10:229-30.
6.   Rosenthal, I. M., M. Zhang, D. Almeida, J. H. Grosset, and E. L. Nuermberger. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 178:989-93.
7.   Nuermberger, E., S. Tyagi, R. Tasneen, K. N. Williams, D. Almeida, I. Rosenthal, and J. H. Grosset. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-4.
8.   Nuermberger, E. 2008. Older antibiotic gains new respect as potent treatment for tuberculosis. Rifapentine is already approved for use with humans. Home Healthc Nurse 26:204-5.
9.   Nuermberger, E. 2008. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 29:542-51.
10.   Dooley, K., C. Flexner, J. Hackman, C. A. Peloquin, E. Nuermberger, R. E. Chaisson, and S. E. Dorman. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 52:4037-42.
11.   Davies, G. R., and E. L. Nuermberger. 2008. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) 88 Suppl 1:S65-74.
12.   Rosenthal, I. M., M. Zhang, K. N. Williams, C. A. Peloquin, S. Tyagi, A. A. Vernon, W. R. Bishai, R. E. Chaisson, J. H. Grosset, and E. L. Nuermberger. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344.
13.   Jain, S. K., S. M. Hernandez-Abanto, Q. J. Cheng, P. Singh, L. H. Ly, L. G. Klinkenberg, N. E. Morrison, P. J. Converse, E. Nuermberger, J. Grosset, D. N. McMurray, P. C. Karakousis, G. Lamichhane, and W. R. Bishai. 2007. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J Infect Dis 195:1634-42.
14.   Davies, G. R., A. S. Pym, D. A. Mitchison, E. L. Nuermberger, and J. H. Grosset. 2007. Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agents Chemother 51:403; author reply 403-4.
15.   Chauty, A., M. F. Ardant, A. Adeye, H. Euverte, A. Guedenon, C. Johnson, J. Aubry, E. Nuermberger, and J. Grosset. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51:4029-35.
16.   Byrne, S. T., S. M. Denkin, P. Gu, E. Nuermberger, and Y. Zhang. 2007. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol 56:1047-51.
17.   Almeida, D., E. Nuermberger, S. Tyagi, W. R. Bishai, and J. Grosset. 2007. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 51:4261-6.
18.   Rosenthal, I. M., K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2006. Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis. Am J Respir Crit Care Med 174:94-101.
19.   Nuermberger, E., I. Rosenthal, S. Tyagi, K. N. Williams, D. Almeida, C. A. Peloquin, W. R. Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50:2621-5.
20.   Zetola, N., J. S. Francis, E. L. Nuermberger, and W. R. Bishai. 2005. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 5:275-86.
21.   Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49:2289-93.
22.   Rosenthal, I. M., K. Williams, S. Tyagi, A. A. Vernon, C. A. Peloquin, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2005. Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in Murine Tuberculosis. Am J Respir Crit Care Med.
23.   Nuermberger, E., S. Tyagi, K. N. Williams, I. Rosenthal, W. R. Bishai, and J. H. Grosset. 2005. Rifapentine, Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med.
24.   Nuermberger, E., K. Helke, and W. R. Bishai. 2005. Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy. Int J Antimicrob Agents.
25.   Nuermberger, E. 2005. Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials. Pharmacotherapy 25:134S-139S.
26.   Francis, J. S., M. C. Doherty, U. Lopatin, C. P. Johnston, G. Sinha, T. Ross, M. Cai, N. N. Hansel, T. Perl, J. R. Ticehurst, K. Carroll, D. L. Thomas, E. Nuermberger, and J. G. Bartlett. 2005. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40:100-7.
27.   Francis, J. S., K. Carroll, E. Nuermberger, and J. G. Bartlett. 2005. Reply to Wargo and Eiland. Clin Infect Dis 40:1378-1379.
28.   Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-4.
29.   Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-6.
30.   Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, W. R. Bishai, and J. H. Grosset. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 72:1065-71.
31.   Nuermberger, E. L., and W. R. Bishai. 2004. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin Infect Dis 38 Suppl 4:S363-71.
32.   Nuermberger, E., and J. Grosset. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 23:243-55.
33.   Nuermberger, E., W. R. Bishai, and J. H. Grosset. 2004. Latent tuberculosis infection. Semin Respir Crit Care Med 25:317-36.
34.   Nuermberger, E., and W. R. Bishai. 2004. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis 38:99-103.
35.   Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2003. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med.
36.   Nuermberger, E. L., and W. R. Bishai. 2003. Significance of macrolide resistance in Streptococcus pneumoniae. J Antimicrob Chemother 52:524-5; author reply 525.
37.   Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 46:1875-9.
38.   Nuermberger, E. 2002. Cases from the Osler medical service at Johns Hopkins university. Am J Med 112:70-1.
39.   Myers, J. S., and E. Nuermberger. 2002. Cases from the Osler Medical Service at Johns Hopkins University. Diagnosis: Polymorphic population of mature and immature hematopoietic cells consistent with extramedullary hematopoiesis. Am J Med 112:494-5.
40.   Lanzkron, S., A. R. Moliterno, E. J. Norris, S. A. Gould, J. Segal, E. L. Nuermberger, and P. M. Ness. 2002. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion 42:1422-7.
41.   Eustace, J. A., E. Nuermberger, M. Choi, P. J. Scheel, Jr., R. Moore, and W. A. Briggs. 2000. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 58:1253-60.
42.   Nuermberger, E. 1999. Current concepts in HIV-associated nephropathy. Hopkins HIV Rep 11:12-4.

Quick Links